指南与共识支持与姑息治疗妇科肿瘤

妊娠期癌症的管理:ASCO指南

Management of Cancer During Pregnancy: ASCO Guideline.
指南 / 共识 · J Clin Oncol · 2025-12-11

ASCO召集多学科专家组系统综述450项研究,多为观察性数据,提出妊娠期癌症管理应基于价值观知情同意,诊断遵循ALARA原则,全身治疗推迟至孕中期,多种药物禁用,计划37周后分娩且末次化疗距分娩2-4周,并强调心理社会支持。

要点

  • 妊娠期癌症管理需基于价值观的知情同意,权衡母胎风险与获益。
  • 诊断评估遵循ALARA原则,全身治疗推迟至孕中期。
  • 甲氨蝶呤、激素治疗、HER2靶向药、VEGF/PARP抑制剂、ADC及细胞疗法全程禁用。

核心结论

  • 妊娠期癌症管理应基于价值观的知情同意,权衡母胎风险与获益,并遵循ALARA原则进行诊断评估。

研究设计与样本

  • 多学科专家组进行系统文献综述,纳入450项符合标准的研究,证据多为观察性数据、病例系列和病例报告。

主要发现

  • 系统综述识别了450项符合标准的研究,证据以观察性数据、病例系列和病例报告为主。

关键数值与推荐

  • 诊断评估应遵循ALARA原则,检查时机根据癌症检测紧迫性、延迟风险及母胎风险平衡个体化。
  • 全身治疗应推迟至孕中期,因对胚胎/胎儿有显著伤害风险。
  • 甲氨蝶呤、激素治疗、HER2靶向药、VEGF和PARP抑制剂、抗体药物偶联物及所有细胞疗法在妊娠期全程禁用。
  • 希望继续妊娠者,计划在37周或之后分娩,末次化疗安排在分娩前2-4周。
  • 转诊至心理社会支持服务至关重要,以应对情绪和实际问题、减少痛苦并支持共享决策。

临床怎么用

  • 临床中应基于价值观知情同意,遵循ALARA原则安排诊断,孕中期前推迟全身治疗,禁用特定药物,37周后计划分娩并调整化疗时间,同时提供心理社会支持。

局限性

  • 证据多为观察性数据、病例系列和病例报告,缺乏随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To provide guidance on the recommended management of cancer in pregnant patients. METHODS: A multidisciplinary Expert Panel convened and conducted a systematic review of the literature. RESULTS: The systematic review identified 450 eligible studies. Much of the evidence consisted of observational data, case series, and case reports. RECOMMENDATIONS: Management of cancer during pregnancy should be grounded in a values-based informed-consent process outlining maternal and fetal risks and anticipated benefits. Diagnostic evaluation should follow the as low as reasonably achievable (ALARA) principle, with timing of diagnostic studies individualized based on urgency of cancer detection, potential dangers of delay, and the balance of risks to both the pregnant patient and her embryo or fetus. Due to significant risk of harm to the developing embryo and/or fetus, systemic therapy should be deferred until the second trimester. Methotrexate, hormonal therapies, human epidermal growth factor receptor 2-targeted agents, vascular endothelial growth factor and poly (ADP-ribose) polymerase inhibitors, antibody-drug conjugates, and all cellular therapies are contraindicated during pregnancy, regardless of gestational age. For patients who wish to continue their pregnancy, delivery should be planned at or after 37 weeks, with the final chemotherapy dose scheduled 2-4 weeks before birth. Referral to psychosocial support services is essential to address emotional and practical challenges, reduce distress, and support shared decision making.Additional information is available at www.asco.org/survivorship-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Loren AW, Lacchetti C, Amant F, et al. Management of Cancer During Pregnancy: ASCO Guideline. J Clin Oncol. 2025. PMID: 41380115. doi:10.1200/JCO-25-02115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。